Invivoscribe appoints Loui Madakamutil to lead its Therapeutics division as Chief Scientific Officer. September 8, 2020 READ MORE ⟶ Newsroom Invivoscribe Launches New Division for Drug Development. Licenses Small Molecule Inhibitors from Domainex to Treat Acute Myeloid Leukemia July 14, 2020 READ MORE ⟶ Newsroom Invivoscribe Announces FDA Approval for Distribution of the LeukoStrat CDx FLT3 Mutation Assay as an IVD Kit in the United States May 19, 2020 READ MORE ⟶ Newsroom Invivoscribe Submits LeukoStrat® CDx FLT3 Mutation Assay to NMPA in China and Expands Company, Adding Laboratory in Shanghai to Provide Comprehensive Support for Partners. May 12, 2020 READ MORE ⟶ Newsroom Invivoscribe Launches COVID-19 Diagnostic Testing with Option to Participate in SARS-CoV-2 Antibody and Vaccine Program April 28, 2020 READ MORE ⟶ Newsroom The European Commission Approves Astellas’ XOSPATA® for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation Detected by Validated Tests, including the Invivoscribe LeukoStrat CDx FLT3 Mutation Assay December 5, 2019 READ MORE ⟶ Newsroom NOW AVAILABLE! MRD solutions for B- and T-cell clonality tracking August 26, 2019 READ MORE ⟶ Newsroom Japan’s MHLW Approves Invivoscribe’s LeukoStrat CDx FLT3 Mutation Assay as the CDx for Daiichi Sankyo’s Quizartinib for Treatment of Relapsed/Refractory FLT3-ITD AML. Expands Use to Include Specimens Collected in EDTA June 19, 2019 READ MORE ⟶ Newsroom Invivoscribe Expanding Clinical Laboratory Network Space and Testing Capabilities in San Diego, Germany, Japan, and China. Offering Comprehensive Standardized Testing for All Hematologic Malignancies May 21, 2019 READ MORE ⟶ Newsroom Invivoscribe To Present At Biotech Showcase™ 2019 In San Francisco January 3, 2019 READ MORE ⟶ Newsroom
Newsroom2019-06-28T07:18:55+00:00